Quantcast

Industry news that matters to you.  Learn more

Berg Joins U.K. Prime Minister’s Initiative, Genomics England to Sequence 100,000 Genomes

Reading time: 2 – 4 minutes

Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will join an industry collaboration with Genomics England. Formed by U.K. Prime Minister David Cameron, Genomics England is partnering with innovative health companies like Berg to accomplish its mission to sequence 100,000 human genomes and create a new genomic medicine service for the National Health Services (NHS) by 2017. The project focuses on patients with rare diseases and six common cancers.

Through the GENE Consortium, Berg will work on an Industry Trial involving a selection of whole genome sequences across cancer and rare diseases, discovering how best to collaborate with clinicians and researchers.  The Trial aims to identify the most effective way of bringing industry expertise into the 100,000 Genomes Project in order to realize the potential benefits for patients.

Berg, the namesake of Chairman and Co-founder Carl E. Berg together with Co-founders Mitch Gray and Niven R. Narain, utilizes deep biological profiling and Bayesian artificial intelligence as a foundation to creating the next generation of drugs and diagnostics to improve human health.

Berg aims to use its expertise in data-analytics, as well as its proprietary Interrogative Biology® Platform in the development of an analytical tool that will be used to process data from the 100,000 Genomes Project.

Berg’s revolutionary drug, BPM 31510, has been engineered to battle some of the most deadly cancers, including highly metabolic tumors. Focused on a precision medicine approach to drug discovery, Berg flips the normal drug development process by creating therapies that match the biology of a disease to produce the right treatment for a specific patient, versus the current one-size-fits-all approach. In addition, Berg’s novel platforms and key relationships like the prostate cancer collaboration with the U.S. Department of Defense has led to new diagnostic markers for prostate cancer and a bold approach underway on pancreatic cancer and Parkinson’s Disease.

“Through our partnership with Genomics England, Berg will use AI-based big data analytics to identify areas in the biology that have been affected by a diseased environment,” said Niven R. Narain, Berg’s co-founder, president and chief technology officer. “There will be novel data developed from this project and our goal is to apply Berg’s technology and expertise in advancing the knowledge learned into an actionable benefit back to society. We are both humbled and excited to bring our technologies into the U.K. and greater European Union.”

The announcement is the latest partnership for Berg, which has established key collaborations with an array of institutions including the U.S. Department of Defense, US National Institutes of Health (NIH), Parkinson’s Institute, Harvard Medical School, MD Anderson Cancer Center, Weill Cornell Medical College, Stanford University Medical Center, and the Cancer Research And Biostatistics (CRAB) /Pancreatic Cancer Research Team.

Source: PR Newswire